Newsroom | 13071 results

RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE’s continued listing standards because the average closing price of the Company’s Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the im...

MAPLE GROVE, Minn.--(BUSINESS WIRE)--Urolution Medical, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its OpenFlo® Urinary Catheter, marking a major milestone as the company advances toward clinical evaluation and commercialization. Cleared for urinary tract drainage in adult patients for indwell periods of up to 30 days, OpenFlo® incorporates a patented architecture that re-engineers key mechanical features of the conventional Foley cath...

GREEN BAY, Wis.--(BUSINESS WIRE)--Healthcare designers are balancing an increasingly complex set of needs: creating welcoming spaces for patients, families, and caregivers while meeting demanding requirements for durability, cleanability, and sustainability. At Healthcare Design Conference + Expo 2026, Pallas Textiles will showcase how its portfolio brings together color, pattern, texture, and nature-inspired design to support healing environments throughout the care journey. From the first mom...

BOCA RATON, Fla.--(BUSINESS WIRE)--SurGenTec®, a privately held medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that it has entered into an exclusive license agreement with Allevion Medical for its patented Vantage™ spinal decompression technology. Under the terms of the agreement, SurGenTec® has secured exclusive rights to Allevion Medical's Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally in...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA). Informed by ongoing dialogue...

MELVILLE, N.Y.--(BUSINESS WIRE)--Henry Schein, Inc. (Nasdaq: HSIC) announced today that Emmanuel Caprais, former Senior Vice President and Chief Financial Officer of ITT, Inc. (NYSE: ITT), has been named the Company’s Senior Vice President and Chief Financial Officer effective November 4, 2026. Mr. Caprais will join the Henry Schein Leadership Team (HSLT) and report to Frederick M. Lowery, Chief Executive Officer of Henry Schein. To support a structured transition, Mr. Caprais will initially se...

DALLAS--(BUSINESS WIRE)--Guide Architecture Expands Healthcare Design Platform with Acquisition of MAIA Consulting...

蒙特利尔--(BUSINESS WIRE)--(美国商业资讯)-- Medisca与EUROAPI建立了战略合作伙伴关系，致力于扩大药物配制用原料药的供应渠道，在北美市场开拓差异化供应渠道，并为国际业务增长和肽类合作建立更广泛的框架。 三十多年来，Medisca始终围绕药品配制商不断变化的需求开展业务。这不仅体现在其选择推向市场的产品上，更延伸至这些产品的制造商、相关文件和技术资料，以及将产品顺利交付给客户的质量管理体系。 与EUROAPI建立的合作伙伴关系进一步推进了这一策略。根据新的战略合作伙伴关系，Medisca成为EUROAPI的首家战略分销合作伙伴，致力于将其在欧洲生产的原料药引入北美配制药市场。此次合作包括选定原料药的独家供应协议，并建立了一个框架，从而随着时间的推移逐步扩大产品供应范围、进军更多市场，并推动制药创新领域的发展。 对客户而言，其价值远不止于在产品目录中增加更多原料药。此次合作在制造专业知识与制剂市场需求之间建立了更紧密的联系，并依托技术信息、产品文档以及Medisca对客户的直接洞察。这使Medisca能够更贴近地响应配制商当前的需求，并随着这些需求的变化持...

MONTREAL--(BUSINESS WIRE)--Medisca and EUROAPI have formed a strategic partnership focused on expanding API access for pharmaceutical compounding, creating differentiated access in North America and establishing a broader framework for international growth and peptide collaboration. For more than three decades, Medisca has built its business around the evolving needs of pharmaceutical compounders. That starts with the products it chooses to bring to market but extends much further to the manufa...

MONTREAL--(BUSINESS WIRE)--Firmy Medisca i EUROAPI zawarły partnerstwo strategiczne, które koncentruje się na rozbudowie dostępu do aktywnych składników farmaceutycznych do leków recepturowych. Jego celem jest stworzenie zróżnicowanego dostępu w Ameryce Północnej oraz stworzenie szerszego kontekstu dla rozwoju międzynarodowego i współpracy w obszarze peptydów. Od ponad 30 lat firma Medisca rozwija swoją działalność wokół zmieniających się potrzeb podmiotów sporządzających leki recepturowe. Wszy...